You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Letetresgene autoleucel

Showing 1 - 25 of 30
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumors Trial in United States (letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine)

Completed
Has Results
  • Neoplasms
  • letetresgene autoleucel (GSK3377794)
  • +2 more
  • Tampa, Florida
  • +5 more
Oct 31, 2022

Tumors Trial in Miami, Tampa, Houston (letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine)

Completed
Has Results
  • Neoplasms
  • letetresgene autoleucel (GSK3377794)
  • +2 more
  • Miami, Florida
  • +2 more
Aug 10, 2021

Tumors Trial in Worldwide (Letetresgene autoleucel)

Active, not recruiting
  • Neoplasms
  • Letetresgene autoleucel
  • Pittsburgh, Pennsylvania
  • +5 more
Aug 7, 2023

Tumors Trial in Worldwide (Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide)

Active, not recruiting
  • Neoplasms
  • Letetresgene autoleucel (lete-cel, GSK3377794)
  • +2 more
  • Duarte, California
  • +36 more
Oct 28, 2022

Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia Trial (Brexucabtagene Autoleucel)

Available
  • Mantle Cell Lymphoma
  • Acute Lymphoblastic Leukemia
  • Brexucabtagene Autoleucel
  • (no location specified)
Mar 17, 2023

Relmacabtagene Autoleucel in Hematologic Malignancies

Not yet recruiting
  • Lymphoma, B-Cell
  • +2 more
  • Relmacabtagene Autoleucel
  • Beijing, Beijing, China
  • +1 more
Nov 15, 2023

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Not yet recruiting
  • Non Hodgkin Lymphoma
  • Long-term Follow-Up
  • Stanford, California
  • +4 more
Oct 30, 2023

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Relmacabtagene Autoleucel in Patients With LBCL

Recruiting
  • Large B-cell Lymphoma
  • Relmacabtagene Autoleucel
  • Shanghai, Shanghai, China
    Ruijin Hospital Affiliated to Shanghai Jiao Tong University Scho
Nov 15, 2023

Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Relmacabtagene Autoleucel
  • +2 more
  • Guangzhou, Guangdong, China
  • +12 more
Oct 24, 2023

Lymphoblastic Leukemia Trial in Palo Alto (Dasatinib)

Not yet recruiting
  • Lymphoblastic Leukemia
  • Palo Alto, California
    Stanford University
Aug 14, 2023

Relapsed/Refractory Mantle Cell Lymphoma Trial in Worldwide (brexucabtagene autoleucel, Cyclophosphamide, Fludarabine)

Active, not recruiting
Has Results
  • Relapsed/Refractory Mantle Cell Lymphoma
  • brexucabtagene autoleucel
  • +3 more
  • Gilbert, Arizona
  • +31 more
Jan 26, 2023

Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt

Not yet recruiting
  • Relapsed/Refractory Waldenstrom Macroglobulinemia
  • +3 more
  • Brexucabtagene Autoleucel
  • +2 more
  • (no location specified)
Sep 8, 2022

Relapsed/Refractory Mantle Cell Lymphoma Trial in Worldwide (Fludarabine, Cyclophosphamide, Brexucabtagene autoleucel)

Recruiting
  • Relapsed/Refractory Mantle Cell Lymphoma
  • Gilbert, Arizona
  • +40 more
Jan 6, 2023

B-cell Lymphoma Trial in Beijing (Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • B-cell Lymphoma
  • Relmacabtagene Autoleucel
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Oct 19, 2022

Multiple Myeloma Trial in Worldwide (JNJ-68284528, Pomalidomide, Bortezomib)

Active, not recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +87 more
Jan 17, 2023

Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma Trial in United States (Afamitresgene

Not yet recruiting
  • Synovial Sarcoma
  • +3 more
  • Afamitresgene autoleucel
  • Palo Alto, California
  • +3 more
Dec 6, 2022

Lymphoma, Mantle Cell Lymphoma Trial in Houston (Acalabrutinib, Rituximab, Brexucabtagene Autoleucel)

Not yet recruiting
  • Lymphoma
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 10, 2022

Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine

Not yet recruiting
  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • Ciltacabtagene Autoleucel
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 2, 2023

Relapsed/Refractory Large B-Cell Lymphoma Trial in Beijing, Hangzhou (Prizloncabtagene autoleucel)

Recruiting
  • Relapsed/Refractory Large B-Cell Lymphoma
  • Prizloncabtagene autoleucel
  • Beijing, China
  • +1 more
Mar 24, 2023

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Trial in Worldwide

Active, not recruiting
  • Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
  • Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
  • Brexucabtagene Autoleucel (KTE-X19)
  • +2 more
  • Los Angeles, California
  • +30 more
Nov 2, 2022

Multiple Myeloma Trial in Worldwide (Bortezomib, Dexamethasone, Lenalidomide)

Recruiting
  • Multiple Myeloma
  • San Francisco, California
  • +152 more
Jan 27, 2023

Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma Trial in Italy, United

Active, not recruiting
Has Results
  • Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma
  • brexucabtagene autoleucel
  • +2 more
  • Phoenix, Arizona
  • +21 more
Jun 2, 2022

Multiple Myeloma Trial in Worldwide (Cilta-cel)

Recruiting
  • Multiple Myeloma
  • Phoenix, Arizona
  • +30 more
Aug 11, 2022

Multiple Myeloma Trial (Cilta-cel OOS Therapy)

Available
  • Multiple Myeloma
  • Cilta-cel OOS Therapy
  • (no location specified)
Aug 15, 2022